(University of Helsinki) Acute lymphoblastic leukaemia (T-ALL) is an aggressive form of blood cancer. Cooperation between Finnish and Chinese research groups has now opened up new opportunities for developing treatments targeting this severe illness.
Rearrangements involving the neurotrophic receptor kinase genes (NTRK1, NTRK2, and NTRK3; hereafter referred to as TRK) produce oncogenic fusions in a wide variety of cancers in adults and children. Although TRK fusions occur in fewer than 1% of all solid tumors, inhibition of TRK results in profound therapeutic responses, resulting in Breakthrough Therapy FDA approval of the TRK inhibitor larotrectinib for adult and pediatric patients with solid tumors, regardless of histology. In contrast to solid tumors, the frequency of TRK fusions and the clinical effects of targeting TRK in hematologic malignancies are unknown. Here,…
(University of Texas M. D. Anderson Cancer Center) Almost one year after the US Food and Drug Administration (FDA) approval of chimeric antigen receptor (CAR) T-cell therapy for children with acute lymphoblastic leukemia (ALL), researchers at The University of Texas MD Anderson Cancer Center and the Pediatric Acute Lung Injury and Sepsis Investigators Network (PALISI) today published treatment guidelines for managing the treatment in the online issue of Nature Reviews Clinical Oncology.
Publication date: August 2018Source: Seminars in Cancer Biology, Volume 51Author(s): Jessica Nordlund, Ann-Christine SyvänenAbstractAcute lymphoblastic leukemia (ALL) is the most common malignancy in children. ALL arises from the malignant transformation of progenitor B- and T-cells in the bone marrow into leukemic cells, but the mechanisms underlying this transformation are not well understood. Recent technical advances and decreasing costs of methods for high-throughput DNA sequencing and SNP genotyping have stimulated systematic studies of the epigenetic changes in leukemic cells from pediatric ALL patients. The re…
Conclusion: Silymarin decreased early Doxorubicin induced left ventricular systolic function disturbances and can be recommended as adjuvant drug in patients with ALL under doxorubicin therapy.
RECOMMENDATION: Multicenter studies on large number of patients with longer duration of follow up to prove the protective effects of silymarin in early and late Doxorubicin induced cardiotoxicity.
PMID: 30073931 [PubMed – as supplied by publisher]
AbstractPhiladelphia (Ph)-like or BCR-ABL like acute lymphoblastic leukemia (ALL) is defined on the basis of a gene expression profile that is similar to Ph-positive ALL. It comprises a wide spectrum of genetic lesions affecting primarily the cytokine receptor and/or kinase signalling genes. It accounts for approximately 10 –15% of pediatric ALL, and is more common in patients who are high-risk according to the National Cancer Institute criteria. Presence of Ph-like mutations is an independent predictor of poor outcome. However, there is vast potential to utilize targeted therapy to improve survival in this group. Th…
Secondary malignancies are broadly defined as a group of cancers arising after a previous malignancy and have become increasingly appreciated due to improvement in cancer survival. Therapy-related malignancies are a sub-group of secondary malignancies in which the exposure to prior chemotherapy or radiation therapy is instrumental to the establishment of the secondary cancer. Other than the role of previous therapies, underlying genetic predisposition, immunodeficiency states or simple coincidence have all also been invoked as potential causative factors for the development of secondary cancers .
ConclusionsOur data suggest that the synergistic anticancer effect induced by combination of MST-312 and doxorubicin represents a novel treatment strategy for pre-B ALL.Graphical abstract
Pediatric Blood&Cancer, EarlyView.
CONCLUSIONS: Holistic patient support-specific activities and adapted protocols made a measurable impact on patient outcomes. High survival outcomes of patients have been achieved despite relatively few receiving salvage therapies or stem cell transplant.
Pediatric Blood&Cancer, EarlyView.